Iloperidone works in synergy with temozolomide to limit the proliferation of glioblastoma cells | [Abstract Book on 9th Annual Neuroscience Conference (ANC-23) August 12-13, 2023 • 2023]

Author(s):

1. Sahar Mubeen: Department of Anatomy, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan

2. Iffat Raza: Department of Anatomy, Karachi Institute of Medical Sciences, Karachi, Pakistan

3. Ather Enam: Department of Surgery, Dow University of Health Sciences, Karachi, Pakistan

4. Badruddin Ujjan: Department of Surgery, Dow University of Health Sciences, Karachi, Pakistan

5. Muhammad Sameer: Department of Surgery, Dow University of Health Sciences, Karachi, Pakistan

6. Lubna Khan: Department of Biochemistry, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan

7. Farina Hanif: Department of Biochemistry, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan

Abstract:

The ability of GBM to infiltrate, multiply, and recur makes it the most deadly and aggressive brain tumor. Additionally, it becomes resistant to medications and radioactive materials, and the grim outlook just makes matters worse. Antipsychotics have the potential to treat GBM and have a propensity to break through resistance. In comparison to other antipsychotics, iloperidone has fewer side effects. Its ability to be repurposed against GBM is still being researched. The purpose of the current study is to determine whether the FDA-approved anti-psychotic drug iloperidone may be used to treat GBM either alone or in combination with the medication temozolamide. Under typical circumstances, the U87 glioma cell line was grown. For 48 hours, the cells were exposed to iloperidone and temozolamide at varying concentrations (10uM to 90uM), both alone and in combination. MTT was used to examine how iloperidone alone and in combination with the common medication temozolamide inhibited growth. The drug interaction coefficient was determined, and doses that demonstrated synergistic activity were then used in the wound healing assay. Image J was used to analyse the wound`s area. The development of U87 cells was greatly slowed down by both iloperidone and temozolomide. The result, nevertheless, was dose independent. Additionally, a synergistic interaction between iloperidone 60 uM and temozolamide 60 uM greatly reduced U87 cell proliferation. Iloperidine and TMZ both prevented U87 from migrating. When U87 cells` migration was inhibited, the synergism was not seen. Iloperidone, an atypical antipsychotic, combined with temozolomide to synergistically decrease the proliferation of U87 cells.

Page(s):

DOI: DOI not available

Published: Journal: Abstract Book on 9th Annual Neuroscience Conference (ANC-23) August 12-13, 2023 , Volume: 0, Issue: 0, Year: 2023

Keywords:

Keywords are not available for this article.

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views